Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Responds to FDA’s Approval for DTC Testing for Three BRCA Gene Mutations
-
ACMG Comments to CMS on Proposed NCD for Coverage of NGS for Medicare Beneficiaries with Advanced Cancer (CAG-00450N)
-
ACMG Letter Regarding South Carolina House Bill 3751 (2017) – Requesting Amendments
-
ACMG Letter Regarding South Carolina Senate Bill 264 (2017) – Requesting Amendments
-
Group Sign-on Letter to Congress Supporting the Local Coverage Determination Clarification Act of 2017
-
ACMG Board Statement Regarding 2018 ACMG Annual Meeting to Be Held in Charlotte, NC and Discriminatory Legislation
-
ACMG Efforts Lead AMA Resolution 122 to Support Coverage of Medical Food Products
-
Joint Comments to CMS Concerning MolDx Program, Medicare Coverage, and Impact on MoPath Gapfill Determinations
-
ACMG Letter to Palmetto GBA Requesting Reconsideration of Cytogenetic Microarray Coverage
-
ACMG Letter Regarding California Assembly Bill 2300 (2010)